Metabolites of Tamoxifen as the Basis of Drug Development

作者: Philipp Y. Maximov , Russell E. McDaniel , V. Craig Jordan

DOI: 10.1007/978-3-0348-0664-0_3

关键词:

摘要: By the early 1970s, a number of metabolites tamoxifen had been identified in animals and following administration to few patients. The hydroxylated metabolite tamoxifen, 4-hydroxytamoxifen, proved be most interesting. discovery its high binding affinity for estrogen receptor made it new laboratory tool all future vitro studies antiestrogen action also provided clue structure-function relationships antiestrogens. These compounds would subsequently developed as selective modulators (SERMs). Tamoxifen is prodrug but 4-hydroxy-N-desmethyltamoxifen or endoxifen that has attracted pharmacogenetic interest. Mutations CYP2D6 gene control production have associated with drug efficacy some clinical trials.

参考文章(141)
Andreas Nüssler, Peter Neuhaus, Ulrich M. Zanger, Michel Eichelbaum, Thomas E. Mürdter, Janet K. Coller, Niels Krebsfaenger, Kathrin Klein, Karin Endrizzi, Renzo Wolbold, Thomas Lang, The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. British Journal of Clinical Pharmacology. ,vol. 54, pp. 157- 167 ,(2002) , 10.1046/J.1365-2125.2002.01614.X
J.L. Borgna, H. Rochefort, Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. Journal of Biological Chemistry. ,vol. 256, pp. 859- 868 ,(1981) , 10.1016/S0021-9258(19)70058-1
M E Lieberman, J Gorski, V C Jordan, An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. Journal of Biological Chemistry. ,vol. 258, pp. 4741- 4745 ,(1983) , 10.1016/S0021-9258(18)32484-0
KAREN E. ALLEN, E.R. CLARK, V.C. JORDAN, Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships British Journal of Pharmacology. ,vol. 71, pp. 83- 91 ,(1980) , 10.1111/J.1476-5381.1980.TB10912.X
Joanne S. L. Lim, Xiang A. Chen, Onkar Singh, Yoon S. Yap, Raymond C. H. Ng, Nan S. Wong, Mabel Wong, Edmund J. D. Lee, Balram Chowbay, Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. British Journal of Clinical Pharmacology. ,vol. 71, pp. 737- 750 ,(2011) , 10.1111/J.1365-2125.2011.03905.X
Leonard J. Lerner, V. Craig Jordan, Development of Antiestrogens and Their Use in Breast Cancer: Eighth Cain Memorial Award Lecture Cancer Research. ,vol. 50, pp. 4177- 4189 ,(1990)
Alma L. Burlingame, William J. Bodell, Krisztina Pongracz, Deena N. Pathak, Takemichi Nakamura, Activation of the Tamoxifen Derivative Metabolite E to Form DNA Adducts: Comparison with the Adducts Formed by Microsomal Activation of Tamoxifen Cancer Research. ,vol. 55, pp. 3012- 3015 ,(1995)
Ian R. Hardcastle, Alan Hewer, David H. Phillips, Martin R. Osborne, Paul L. Carmichael, Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen Cancer Research. ,vol. 56, pp. 66- 71 ,(1996)
Anait S. Levenson, V. Craig Jordan, The Key to the Antiestrogenic Mechanism of Raloxifene Is Amino Acid 351 (Aspartate) in the Estrogen Receptor Cancer Research. ,vol. 58, pp. 1872- 1875 ,(1998)
M E Lieberman, V C Jordan, M Fritsch, M A Santos, J Gorski, Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro. Journal of Biological Chemistry. ,vol. 258, pp. 4734- 4740 ,(1983) , 10.1016/S0021-9258(18)32483-9